AC Immune S.A. (ACIU) Stock Price, Quote & News

Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, confor...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 21 345 91 21

Fax: 41 21 345 91 20

Website: www.acimmune.com

Address:

Building B, EPFL Innovation Park, Lausanne, Switzerland

midas7576 Mar. 16 at 2:00 PM

$ACIU

0 · Reply

erevnon Mar. 16 at 10:55 AM

BTIG reiterates AC Immune $ACIU at Buy and maintains the price target at https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Trip1801 Mar. 13 at 2:14 PM

$ACIU https://www.globenewswire.com/news-release/2026/03/13/3255371/0/en/AC-Immune-Reports-Full-Year-2025-Financial-Results-and-Provides-a-Corporate-Update.html

0 · Reply

lucabrix Mar. 10 at 9:05 PM

$ACIU run to 4 and then lets hope!

0 · Reply

BillionerOfKing Mar. 6 at 5:56 PM

$ACIU Current Stock Price: $2.72 Contracts to trade: $5.0 ACIU Mar 20 2026 Call Entry: $0.05 Exit: $0.06 ROI: 42% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

midas7576 Mar. 5 at 1:24 PM

$ACIU AC Immune will also present its first-in-class TDP-43 PET-tracer on ACI-19626 at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2026) taking place in Copenhagen, Denmark, on March 17-21, 2026. Industry Symposium: From Treatment to Prevention in Parkinson’s Disease Session Date/Time: Wednesday, March 18, 2026, 8:40 – 10:40 am CET Location: Hall A1 Opening and Closing Remarks: Andrea Pfeifer, Ph.D., CEO of AC Immune Shifting treatment to prevention: lessons learned from Alzheimer’s disease Presenter: Prof. Catherine Mummery (University College London) Time: 8:45 – 9:00 am CET Targeting α-synuclein in Parkinson’s disease: pathophysiology and supporting evidence Presenter: Werner Poewe, M.D. (Medical University of Innsbruck) Time: 9:00 – 9:25 am CET Misfolding of α-synuclein as fluid biomarker measured with the iRS platform of betaSENSE Presenter: Prof. Klaus Gerwert (Centre for Protein Diagnostics at Ruhr University Bochum) Time: 9:25 – 9:40

0 · Reply

midas7576 Mar. 5 at 1:22 PM

$ACIU AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 05/03/2026 12:00pm GlobeNewswire Inc. AC Immune (NASDAQ:ACIU) Intraday Stock Chart Thursday 5 March 2026 Click Here for more AC Immune Charts. AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 AC Immune to host symposium highlighting Precision Prevention approach to Parkinson's disease Presentation at International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD™ 2026) showcases potential of first-in-class TDP-43 PET-tracer ACI-19626 Lausanne, Switzerland, March 5, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will host an industry symposium on how a precision prevention approach to Parkinson’s disease may now be within reach, based on lessons from Alzheimer’s disease.

0 · Reply

DARKP00L Feb. 24 at 1:01 PM

$ACIU 07:18 on Feb. 24 2026 AC Immune Doses First Participant In Phase 1 Study Of ACI-19764 Targeting Neuroinflammation In Alzheimer's, Parkinson's And ALS #tradeideas

0 · Reply

Ou8mycookie Feb. 20 at 7:18 PM

$ACIU makes sense for JNJ to pause recruitment for retain with the uttter failure of posidinemab. They’ll need to continue to analyze the data of current patients to see if vaccine induced antibodies are more specific for tau proteins and maybe effective at the preclinical stage vs early stage AD that posidinemab was targeting. Tau theory is still viable target. And still have the relatively recent big partnership with takeda targeting Abeta. I think the biggest potential value for company now is Parkinson’s vaccine targeting Asyn. I don’t recall the company hinting at any patient clinical signs of improvement for any press releases. They did with 7104.056

0 · Reply

papatrick Feb. 19 at 1:29 PM

$ACIU rather think it's over with ACIU and AD potential...like the whole antibody theory...over and dead...from an injection or from your own immune system. No effect on cognition

0 · Reply

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

Dec 15, 2025, 2:50 PM EST - 3 months ago

AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD

Dec 11, 2025, 12:47 PM EST - 3 months ago

AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's

Dec 11, 2025, 7:00 AM EST - 3 months ago

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease

Nov 4, 2025, 7:00 AM EST - 4 months ago

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Oct 24, 2025, 8:50 AM EDT - 5 months ago

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine

Aug 5, 2025, 7:00 AM EDT - 7 months ago

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Apr 30, 2025, 7:00 AM EDT - 11 months ago

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 2, 2025, 6:00 AM EDT - 1 year ago

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

Mar 25, 2025, 7:00 AM EDT - 1 year ago

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

Mar 13, 2025, 7:00 AM EDT - 1 year ago

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

Nov 14, 2024, 10:32 AM EST - 1 year ago

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients

Jul 31, 2024, 8:30 AM EDT - 1 year ago

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

Jul 26, 2024, 3:10 PM EDT - 1 year ago

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

Jul 25, 2024, 7:00 AM EDT - 1 year ago

AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease

May 28, 2024, 7:00 AM EDT - 1 year ago

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

May 13, 2024, 8:47 AM EDT - 2 years ago

Alzheimer's vaccine licensing deal boosts AC Immune

May 13, 2024, 6:05 AM EDT - 2 years ago

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 13, 2024, 6:00 AM EDT - 2 years ago

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease

TAK

Mar 14, 2024, 7:00 AM EDT - 2 years ago

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Feb 22, 2024, 7:00 AM EST - 2 years ago

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

Jan 22, 2024, 7:00 AM EST - 2 years ago

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

Jan 3, 2024, 8:10 AM EST - 2 years ago

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

Dec 18, 2023, 6:25 PM EST - 2 years ago

AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts

Dec 15, 2023, 7:56 AM EST - 2 years ago

AC Immune Announces Pricing of Underwritten Offering of Common Shares

Dec 15, 2023, 7:22 AM EST - 2 years ago

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial

Dec 1, 2023, 7:00 AM EST - 2 years ago

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

Nov 7, 2023, 7:00 AM EST - 2 years ago

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

Nov 3, 2023, 7:00 AM EDT - 2 years ago

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Nov 2, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023

Oct 27, 2023, 7:00 AM EDT - 2 years ago

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic

Oct 17, 2023, 7:00 AM EDT - 2 years ago

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

Oct 5, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

Sep 5, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

Aug 4, 2023, 7:00 AM EDT - 2 years ago

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Jul 28, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

Jul 26, 2023, 7:00 AM EDT - 2 years ago

AC Immune SA Appoints New Chief Medical Officer

Jul 3, 2023, 7:00 AM EDT - 2 years ago

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

Jun 27, 2023, 7:52 AM EDT - 2 years ago

AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment

Jun 27, 2023, 7:00 AM EDT - 2 years ago

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's Disease

Jun 23, 2023, 4:30 PM EDT - 2 years ago

AC Immune Holds Annual General Meeting of Shareholders

Apr 28, 2023, 7:00 AM EDT - 3 years ago

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Apr 5, 2023, 7:00 AM EDT - 3 years ago

AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer's Disease

Mar 20, 2023, 8:00 AM EDT - 3 years ago

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

Mar 18, 2023, 9:00 AM EDT - 3 years ago

AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures

Mar 16, 2023, 7:00 AM EDT - 3 years ago

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 8, 2023, 7:00 AM EST - 3 years ago

AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023

Feb 7, 2023, 7:00 AM EST - 3 years ago

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

Feb 2, 2023, 8:15 AM EST - 3 years ago

AC Immune to Present at the SVB Securities Global Biopharma Conference

Jan 26, 2023, 7:00 AM EST - 3 years ago

AC Immune's ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer's Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

midas7576 Mar. 16 at 2:00 PM

$ACIU

0 · Reply

erevnon Mar. 16 at 10:55 AM

BTIG reiterates AC Immune $ACIU at Buy and maintains the price target at https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Trip1801 Mar. 13 at 2:14 PM

$ACIU https://www.globenewswire.com/news-release/2026/03/13/3255371/0/en/AC-Immune-Reports-Full-Year-2025-Financial-Results-and-Provides-a-Corporate-Update.html

0 · Reply

lucabrix Mar. 10 at 9:05 PM

$ACIU run to 4 and then lets hope!

0 · Reply

BillionerOfKing Mar. 6 at 5:56 PM

0 · Reply

midas7576 Mar. 5 at 1:24 PM

0 · Reply

midas7576 Mar. 5 at 1:22 PM

0 · Reply

DARKP00L Feb. 24 at 1:01 PM

$ACIU 07:18 on Feb. 24 2026 AC Immune Doses First Participant In Phase 1 Study Of ACI-19764 Targeting Neuroinflammation In Alzheimer's, Parkinson's And ALS #tradeideas

0 · Reply

Ou8mycookie Feb. 20 at 7:18 PM

0 · Reply

papatrick Feb. 19 at 1:29 PM

$ACIU rather think it's over with ACIU and AD potential...like the whole antibody theory...over and dead...from an injection or from your own immune system. No effect on cognition

0 · Reply

midas7576 Feb. 18 at 7:43 PM

$ACIU Why a Takeover Might Happen Now De-risked Technology: The Janssen pause happened after meeting an interim immunogenicity threshold, meaning the "SupraAntigen" platform is scientifically validated. Cleaned-Up Operations: In late 2025, AC Immune reduced its workforce by 30% to sharpen its focus on key clinical programs. This "leaner" structure is often a precursor to acquisition. Low Valuation vs. High Potential: With a cash runway into Q3 2027 and a market cap that hasn't fully priced in the $4.5 billion in potential milestones, a "Big Pharma" company could see it as a bargain

0 · Reply

Bbboston Feb. 18 at 6:47 PM

$ACIU Somebody clearly moved out or reduced position. Just saying.

0 · Reply

midas7576 Feb. 18 at 2:40 PM

$ACIU Drop over done -

0 · Reply

BLD33 Feb. 18 at 2:29 PM

$SNSE how many weakness moments were the Opportunity moments to buy The same with $ACIU I’m buying more $JNJ partnership will last and stock will make 100-300-500% gains

0 · Reply

OfficialStocktwitsUser Feb. 16 at 10:11 PM

$ACIU RSI: 32.37, MACD: -0.0977 Vol: 0.24, MA20: 3.28, MA50: 3.23 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BillionerOfKing Feb. 10 at 9:29 PM

$ACIU Current Stock Price: $3.03 Contracts to trade: $2.5 ACIU Feb 20 2026 Call Entry: $0.59 Exit: $1.12 ROI: 91% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

wyoming2020 Feb. 7 at 12:27 PM

$FHTX CEO big buy at Foghorn $ACIU $PDSB fam check it out

0 · Reply

Doru56 Feb. 6 at 2:01 AM

$ACIU The company screwed up something, I was expecting $6-$7 Jan-Feb looks like we go back to $2.X 😬

0 · Reply

Doru56 Feb. 4 at 3:23 PM

$ACIU Did they fired the wrong people last year?

0 · Reply

Ou8mycookie Feb. 2 at 12:47 AM

$ACIU https://scitechdaily.com/scientists-uncover-a-hidden-early-stage-of-alzheimers-that-they-can-stop/

0 · Reply

Market Cap	302.74M
Revenue (ttm)	31.02M
Net Income (ttm)	-57.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-186.46%
Debt to Equity Ratio	0.00

Volume	255,600
Avg Vol	358,340
Day's Range	N/A - N/A
Shares Out	100.41M
Stochastic %K	60%
Beta	1.64
Analysts	Strong Sell
Price Target	$9.00